Skip to main content

-

JCI-2012-14025

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Contratación e Incorporación de RRHH
Subprogram Subprograma Juan de la Cierva (JDC)
Call Juan de la Cierva Incorporación
Call year 2012
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Extracellular vesicles do not contribute to higher circulating levels of soluble 1 in idiopathic dilated cardiomyopathy

  • Rudilla, F..
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Valero, Ana Gámez
  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Soler Botija, Carolina
  • Llucià-Valldeperas, Aida
  • Perea Gil, Isaac
  • Iborra Egea, Oriol|||0000-0002-7280-859X
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Lupón, Josep|||0000-0002-5601-9611
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Idiopathic dilated cardiomyopathy () is a frequent cause of heart transplantation. Potentially valuable blood markers are being sought, and low-density lipoprotein receptor-related protein 1 (1) has been linked to the underlying molecular basis of the disease. This study compared circulating levels of soluble 1 (1) in patients and healthy controls and elucidated whether 1 is exported out of the myocardium through extracellular vesicles (s) to gain a better understanding of the pathogenesis of the disease. 1 α chain expression was analysed in samples collected from the left ventricles of explanted hearts using immunohistochemistry. 1 concentrations were determined in platelet-free plasma by enzyme-linked immunosorbent assay. Plasma-derived s were extracted by size-exclusion chromatography () and characterized by nanoparticle tracking analysis and cryo-transmission electron microscopy. The distributions of vesicular (9, 81) and myocardial (caveolin-3) proteins and 1 α chain were assessed in fractions by flow cytometry. 1 α chain was preferably localized to blood vessels in compared to control myocardium. Circulating 1 was increased in patients. 9- and 81-positive fractions enriched with membrane vesicles with the expected size and morphology were isolated from both groups. The 1 α chain was not present in these fractions, which were also positive for caveolin-3. The increase in circulating 1 in patients may be clinically valuable. Although s do not contribute to higher 1 levels in , a comprehensive analysis of content would provide further insights into the search for novel blood markers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme

  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Lupón, Josep|||0000-0002-5601-9611
  • Domingo, Mar|||0000-0002-2935-1272
  • Stut, Wim
  • Dovancescu, Silviu
  • Cleland, John
  • Frankenstein, Lutz
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Aims: There is a need for alternative strategies that might avoid recurrent admissions in patients with heart failure. home telemonitoring (HTM) to monitor patient's symptoms from a distance may be useful. This study attempts to assess changes in HTM vital signs in response to daily life activities (variations in medication, salt intake, exercise, and stress) and to establish which variations affect weight, blood pressure, and heart rate. Methods and results: We assessed 76 patients with heart failure (mean age 76 ± 10.8 years, 75% male, mainly in NYHA class II/III and from ischaemic aetiology cause). Patients were given a calendar of interventions scheduling activities approximately twice a week before measuring their vital signs. Eating salty food or a large meal were the activities that had a significant impact on weight gain (+0.3 kg; P<0.001 and P = 0.006, respectively). Exercise and skipping a dose of medication other than diuretics increased heart rate (+3 bpm, P = 0.001 and almost +2 bpm, P = 0.016, respectively). Conclusions: Our HTM system was able to detect small changes in vital signs related to these activities. Further studies should assess if providing such a schedule of activities might be useful for patient education and could improve long-term adherence to recommended lifestyle changes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar, the AGTP II trial

  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
  • Cámara, Maria-Luisa|||0000-0002-5204-1459
  • Bustamante-Munguira, Juan|||0000-0002-6542-4504
  • García-Pavía, Pablo|||0000-0002-5470-2257
  • Avanzas, Pablo|||0000-0002-4958-6108
  • San Román, José Alberto|||0000-0003-0764-0839
  • Pascual-Figal, DA.|||0000-0002-4993-9540
  • De Teresa, Eduardo
  • Crespo-Leiro, Maria Generosa|||0000-0002-3085-167X
  • Manito, Nicolás
  • Núñez, Julio|||0000-0003-1672-7119
  • Fernández Avilés, Francisco|||0000-0001-5501-5275
  • Caballero, Ángel
  • Teis, Albert|||0000-0002-4820-0736
  • Lupón, Josep|||0000-0002-5601-9611
  • Brugada, Ramon|||0000-0001-6607-3032
  • Martín, Carlos
  • Silva, Jacobo
  • Revilla-Orodea, Ana
  • Cánovas López, Sergio Juan
  • Melero, Jose M.
  • Cuenca Castillo, José
  • Gonzalez-Pinto, Angel
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Cardiac adipose tissue is a source of progenitor cells with regenerative capacity. Studies in rodents demonstrated that the intramyocardial delivery of cells derived from this tissue improves cardiac function after myocardial infarction (MI). We developed a new reparative approach for damaged myocardium that integrates the regenerative properties of cardiac adipose tissue with tissue engineering. In the adipose graft transposition procedure (AGTP), we dissect a vascularised flap of autologous pericardial adipose tissue and position it over the myocardial scarred area. Following encouraging results in acute and chronic MI porcine models, we performed the clinical trial (NCT01473433, AdiFLAP trial) to evaluate safety in patients with chronic MI undergoing coronary artery bypass graft. The good safety profile and trends in efficacy warranted a larger trial. The AGTP II trial (NCT02798276) is an investigator initiated, prospective, randomised, controlled, multicentre study to assess the efficacy of the AGTP in 108 patients with non-revascularisable MI. Patients will be assigned to standard clinical practice or the AGTP. The primary endpoint is change in necrotic mass ratio by gadolinium enhancement at 91 and 365 days. Secondary endpoints include improvement in regional contractibility by MRI at 91 and 365 days; changes in functional MRI parameters (left ventricular ejection fraction, left and right ventricular geometric remodelling) at 91 and 365 days; levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) at 7, 91 and 365 days; appearance of arrhythmias from 24 hour Holter monitoring at 24 hours, and at 91 and 365 days; all cause death or re-hospitalisation at 365 days; and cardiovascular death or re-hospitalisation at 365 days. The institutional review board approved the trial which will comply with the Declaration of Helsinki. All patients will provide informed consent. It may offer a novel, effective and technically simple technique for patients with no other therapeutic options. The results will be submitted to indexed medical journals and national and international meetings. ClinicalTrials.gov: NCT02798276, pre-results.